# A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

Source: https://onco.cc/trials/nct07634471/  
OnCo record `nct07634471` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial testing MK-1045 in follicular lymphoma, now recruiting.

## Summary

A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) is a phase 2/3 interventional study registered as NCT07634471, led by Merck Sharp & Dohme, and recruiting on the registry. Official title: A Phase 2/3 Randomised, Open-label Study of MK-1045 in Combination With Rituximab in Participants With 1L Follicular Lymphoma. Planned enrolment is 960 participants (estimated). The study started in 2026-06-22 and primary completion is expected in 2032-07-23. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT07634471
- Phase: 2/3
- Setting: A Phase 2/3 Randomized, Open-label Study of MK-1045 in Combination With Rituximab in Participants With 1L Follicular Lymphoma
- Sponsor: Merck Sharp & Dohme
- Enrolled: 960

## Sources

- ClinicalTrials.gov NCT07634471: https://clinicaltrials.gov/study/NCT07634471

## Connected records

- cancers: [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/)
- drugs: [MK-1045](https://onco.cc/drugs/mk-1045/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct07634471.json